Abstract: Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient.
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
Type:
Application
Filed:
December 22, 2022
Publication date:
June 29, 2023
Applicants:
AMGEN INC., Atara Biotherapeutics, Inc.
Inventors:
Huiquan HAN, Christopher Michael HAQQ, Isaac CIECHANOVER, Xiaolan ZHOU, John Zhao-Nian LU
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
Type:
Grant
Filed:
December 13, 2019
Date of Patent:
January 3, 2023
Assignee:
Atara Biotherapeutics, Inc.
Inventors:
Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover, Xiaolan Zhou, John Zhao-Nian Lu
Abstract: Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient.
Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
August 6, 2013
Assignee:
Atara Biotherapeutics, Inc.
Inventors:
Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou, John Lu
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
Type:
Grant
Filed:
November 25, 2009
Date of Patent:
April 2, 2013
Assignee:
Atara Biotherapeutics, Inc.
Inventors:
Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas C. Boone, Rohini Deshpande, Yue-Sheng Li, Hq Han